Antiarrhythmic Drug Management in AF

The first-line antiarrhythmic drug was propafenone (600 mg per day). However, amiodarone (200 mg per day) or sotalol (160 mg per day) was administered when propafenone was contraindicated. Rate control drugs, including beta receptor blockers, calcium channel blockers, and digoxin, were administered as necessary. The use of ARB or ARNI was based on the recommended guideline and physician’s choice, and the dosages were adjusted according to blood pressure, and individual tolerance^{36 (link),37 (link)}. The estimated risk of thromboembolism was calculated for each patient based on the CHA2DS2-VASc. Oral anticoagulants, including warfarin, dabigatran, and rivaroxaban, were recommended to prevent ischemic stroke in patients with a CHA2DS2-VASc score greater than 1 in males or greater than 2 in females.

Free full text: Click here

Dong Y., Zhai Z., Wang J., Xia Z., Xia Z., Zhu B., Dong Q., Li Q, & Li J. (2023). Angiotensin receptor-neprilysin inhibitor delays progression from paroxysmal to persistent atrial fibrillation. Scientific Reports, 13, 3140.

Publication 2023

Amiodarone Antiarrhythmic drug Anticoagulants Beta blockers Blood pressure Calcium channel blockers Dabigatran Digoxin Females Ischemic stroke Males Patients Physician Propafenone Rivaroxaban Sotalol Thromboembolism Warfarin

Corresponding Organization :

Other organizations : Second Affiliated Hospital of Nanchang University, Nanchang University

Top 5 similar protocols

Variable analysis

independent variables

First-line antiarrhythmic drug (propafenone, amiodarone, or sotalol)
Rate control drugs (beta receptor blockers, calcium channel blockers, and digoxin)
Use of ARB or ARNI
Dosages of ARB or ARNI

dependent variables

Outcome of antiarrhythmic drug treatment
Outcome of rate control drug treatment
Outcome of ARB or ARNI treatment

control variables

CHA2DS2-VASc score for estimating thromboembolism risk
Blood pressure
Individual tolerance to medications

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!